Genomic diagnosis for pediatric disorders: revolution and evolution
Powerful, recent advances in technologies to analyze the genome have had a profound
impact on the practice of medical genetics, both in the laboratory and in the clinic. Increasing …
impact on the practice of medical genetics, both in the laboratory and in the clinic. Increasing …
[HTML][HTML] Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups
C Egan, A Nicolae, J Lack, HJ Chung… - …, 2020 - ncbi.nlm.nih.gov
Histiocytic sarcoma is a rare malignant neoplasm that may occur de novo or in the context of
a previous hematologic malignancy or mediastinal germ cell tumor. Here, we performed …
a previous hematologic malignancy or mediastinal germ cell tumor. Here, we performed …
After 95 years, it's time to eRASe JMML
S Meynier, F Rieux-Laucat - Blood Reviews, 2020 - Elsevier
Juvenile myelomonocytic leukaemia (JMML) is a rare clonal disorder of early childhood.
Constitutive activation of the RAS pathway is the initial event in JMML. Around 90% of …
Constitutive activation of the RAS pathway is the initial event in JMML. Around 90% of …
Juvenile myelomonocytic leukemia–A bona fide RASopathy syndrome
T Lasho, MM Patnaik - Best Practice & Research Clinical Haematology, 2020 - Elsevier
Juvenile myelomonocytic leukemia (JMML) is a pediatric myelodysplastic/myeloproliferative
neoplasm overlap syndrome with sustained peripheral blood monocytosis, aggressive …
neoplasm overlap syndrome with sustained peripheral blood monocytosis, aggressive …
Genetic and epigenetic factors interacting with clonal hematopoiesis resulting in chronic myelomonocytic leukemia
RM Carr, MM Patnaik - Current opinion in hematology, 2020 - journals.lww.com
Despite relatively few 'driver'mutations in CMML, evolutionary development of chronic
leukemia remains incompletely understood. Recent studies have shed light on the …
leukemia remains incompletely understood. Recent studies have shed light on the …
Drug repositioning for Noonan and LEOPARD syndromes by integrating transcriptomics with a structure-based approach
Noonan and LEOPARD syndromes (NS and LS) belong to a group of related disorders
called RASopathies characterized by abnormalities of multiple organs and systems …
called RASopathies characterized by abnormalities of multiple organs and systems …
Comprehensive genomic analysis of Noonan syndrome and acute myeloid leukemia in adults: a review and future directions
MS Alhumaid, MJ Dasouki, SO Ahmed… - Acta …, 2020 - karger.com
Acute myeloid leukemia (AML) in the setting of Noonan syndrome (NS) has been reported
before without clear guidelines for treatment or prognosis in these subgroups of patients …
before without clear guidelines for treatment or prognosis in these subgroups of patients …
Rapid detection by hydrops panel of Noonan syndrome with PTPN11 mutation (p.Thr73Ile) and persistent thrombocytopenia
M Schönfeld, M Selig, A Russo… - … Genetics & Genomic …, 2020 - Wiley Online Library
Background Nonimmune hydrops fetalis (NIHF) is still a challenging diagnosis. The
differential diagnosis is extensive and the success of identifying a cause depends on the …
differential diagnosis is extensive and the success of identifying a cause depends on the …
RAS pathway mutation patterns in patients with juvenile myelomonocytic leukemia: a developing country single-center experience
N Hamdy, H Bokhary, A Elsayed, W Hozayn… - … Myeloma and Leukemia, 2020 - Elsevier
Introduction Juvenile myelomonocytic leukemia (JMML) is a rare clonal myelodysplastic/
myeloproliferative neoplasm of early childhood. Historically, it was difficult to diagnose …
myeloproliferative neoplasm of early childhood. Historically, it was difficult to diagnose …
Juvenile Myelomonocytic Leukemia (JMML): A Mimicker of KMT2A-Rearranged Acute Myeloid Leukemia (AML)
AA Saad - Acute Leukemias, 2020 - books.google.com
Juvenile myelomonocytic leukemia (JMML) is the most confusing mimicker of KMT2A-
rearranged acute myeloid leukemia (AML). Clinical presentation, age of susceptibility …
rearranged acute myeloid leukemia (AML). Clinical presentation, age of susceptibility …